Publication Details
Abstract
Background: Inflammation, organ damage, and endothelial dysfunction characterize preeclampsia, a pregnancy-specific multisystem hypertension disease. Adipokines, particularly resistin and adiponectin, have been identified as possible participants in the metabolic and inflammatory pathways that may be involved in the development of disease. Objective: The purpose of this research was to examine the relationship between preeclampsia serum adiponectin and resistin levels and their function as early diagnostic and disease severity predictive markers. Methods: There were 88 pregnant women in this case-control research; 30 were healthy controls, 29 had mild preeclampsia, and 29 had severe preeclampsia. The guidelines set out by the American College of Obstetricians and Gynecologists were used to define preeclampsia. An ELISA was used to ascertain the amounts of resistin and serum adiponectin. On automated analyzers, routine parameters related to renal and hepatic biochemistry were measured. For group comparisons, either Kruskal-Wallis or ANOVA tests were utilized. The use of Spearman coefficients allowed for the evaluation of correlations. In order to find independent factors that could predict the presence and severity of the disease, logistic regression models were developed. In order to evaluate the efficacy of the diagnostic, ROC curve analysis was performed. Results: The levels of resistin and adiponectin were found to be significantly higher in the mild and severe preeclampsia groups compared to the control group (p < 0.001). Strong associations were seen with systolic blood pressure (r = 0•816, p <0•0001), uric acid (r = 0•49, p = 0•0001), and gestational age (r =.477, p= 0•0002), and resistin had a clear progressive rise (8.55 ± 1.43 vs 10.98 ± 1.06 vs 14.16 ± 1.04 mg/L). Even while adiponectin increased (5.05 ± 1.19 vs 10.93 ± 2.43 vs 16.83 ± 4.19 mg/L), it was not as effective in differentiating between the groups. As compared to adiponectin, resistin performed better in ROC analysis for severe preeclampsia (AUC = 0.980 vs. 0.866). Resistin was found to be a significant predictor of both preeclampsia and the severity of the condition, according to logistic regression (OR = 4.93, 95% CI: 2.31-10.54, p < 0.001). Conclusions: Serum resistin outperforms adiponectin in both diagnostic and prognostic tests, and its rise is linked to the severity of preeclampsia. For the purpose of risk stratification and severity evaluation in preeclampsia, resistin could be a clinically valuable supplementary biomarker.